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Among the 2,105 Enterobacteriaceae tested in a survey done in Portugal, 165 were nonsusceptible to carbapenems, fromwhich
35 (26 Klebsiella pneumoniae, 3 Escherichia coli, 2 Enterobacter aerogenes, and 3 Enterobacter cloacae isolates and 1 Klebsiella
oxytoca isolate) were confirmed to be carbapenemase producers by the presence of 30 Tn4401d-blaKPC-3, 4 intI3-blaGES-5, and one
intI1-blaVIM-2 gene, alone or in combination with other bla genes. The dissemination of blaKPC-3 gene carried by an IncF plasmid
suggests lateral gene transfer as a major mechanism of dissemination.
Carbapenem-nonsusceptible Enterobacteriaceae are increas-ingly reported worldwide, mainly because of the acquisi-
tion of carbapenemase-encoding genes located on highly mo-
bile genetic elements (e.g., plasmids and/or integrons) that
facilitate their horizontal spread (1, 2). In Portugal, little is
known regarding the molecular epidemiology of carbapen-
emase-producing Enterobacteriaceae (CPE). Indeed, only spo-
radic isolates or single hospital cases have been described (3),
namely, a VIM-2-producing Klebsiella oxytoca isolate (4), 2 VIM-
34-producing Klebsiella pneumoniae isolates (5), and 6 K. pneu-
moniae carbapenemase (KPC)-3-producing Enterobacteriaceae
isolates (6). The objectives of this study were to (i) characterize a
large number of CPE isolates recovered from different Portuguese
health care institutions, (ii) determine the potential diversity of
these isolates, and (iii) describe the respective plasmids harboring
carbapenemase-encoding genes in an international context.
This study included 2,105 consecutive and nonrepetitive clin-
ical Enterobacteriaceae isolates that were collected between April
2006 and February 2013 and sent to the National Reference Lab-
oratory of Antimicrobial Resistances at the National Institute of
Health, as an integrative part of the Antimicrobial Resistance Sur-
veillance Program in Portugal (ARSIP) laboratory. ARSIP is a vol-
untary Portuguese surveillance program that continually moni-
tors the susceptibilities of pathogens of clinical importance against
several antibiotics. Thirteen Portuguese hospitals located in five
different regions (North, Central, Lisbon andTagusValley, South,
and Autonomous Region of Madeira) participated in this survey.
The screening of carbapenem susceptibility, performed by the
disk diffusionmethod, according to the French Society forMicro-
biology (http://www.sfm-microbiologie.org/), revealed that 165
(7.8%) isolates were ertapenem-nonsusceptible, and these were
selected for further analysis. In addition, clinical isolates showing
an inhibition of carbapenemase, as evidenced by the synergy be-
tween carbapenems (imipenem, meropenem, and/or ertapenem)
and 3-aminophenylboronic acid or EDTA, were considered pre-
sumptive carbapenemase producers from class A or B, respec-
tively (7).
Thirty-five isolates suspected to produce CPE (35/168
[20.8%]) demonstrated a positive synergy between carbapen-
ems and 3-aminophenylboronic acid (n  34) or with EDTA
(n  1), indicative of serine or metallo--lactamase produc-
tion, respectively. The majority of those isolates were collected
from urine samples (54.3%) from elderly (65 years old) male
patients (54.3%), admitted to the emergency room/ambula-
tory (22.9%), internal medicine (17.1%), or surgery (17.1%)
wards. The diminished susceptibilities to carbapenems among
the remaining 130 ertapenem-nonsusceptible isolates (59 Kleb-
siella spp., 28 Enterobacter spp., 23 Escherichia coli, 11Morganella
morganii, 8 Proteus mirabilis, and 1 Serratia marcescens) suggested
a decrease in the outermembrane permeability associatedwith the
weak hydrolytic activity of carbapenems due to the expression of a
-lactamase, such as extended-spectrum -lactamases (ESBLs),
and/or AmpC overexpression (7).
TheMICs of the 35/168 isolates were obtained by the reference
microdilution broth method (8, 9), according to the EUCAST
guidelines (http://www.eucast.org/clinical_breakpoints/). Tige-
cycline and ciprofloxacin were potent against 57.1% and 28.6% of
the isolates, respectively, but colistin was the only antibiotic effec-
tive against all CPE isolates; all isolates were multidrug resistant
(MDR), i.e., presented reduced susceptibility to three or more
structurally unrelated antibiotics (10) (Table 1).
PCR amplification and DNA sequencing were applied to the
165 ertapenem-nonsusceptible isolates to identify the presence or
confirm the absence of the carbapenemase-encoding genes blaKPC
and blaGES (class A), blaIMP, blaVIM, and blaNDM (class B), and
blaOXA-48 (class D) (11). Among the 165 isolates, only the 35 iden-
tified as carbapenemase-producing isolates were confirmed to be
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CPE by the presence of 30 blaKPC-3 and 4 blaGES-5 genes and 1
blaVIM-2 gene, alone or in combinationwith other bla genes (Table
2) (11).
An analysis of the genetic elements associated with the CPE-
encoding genes showed that all the blaKPC-3 genes were flanked by
ISKpn7 on the right and ISKpn6 on the left (12) and a Tn3-like
Tn4401 transposon, with a 68-bp deletion upstream of blaKPC-3,
corresponding to the isoform d. This uncommon isoform has
been described so far only in KPC-producing K. pneumoniae
strains with high-level carbapenem resistance in the United States
and Canada (13–15).
Regarding the blaGES-5 genes, the PCR results and sequence
analysis, using previously described primers (11), revealed the
amplification of the intI3-blaGES-5 region, where the intI3 genewas
located adjacent to the blaGES-5 gene in a configuration previously
reported for the blaGES-1 gene (16, 17). intI3 was targeted and
amplified with a set of primer pairs (5=-GCAAGTGGGTGGCGA
ATG-3= and 5=-CTGAAGTCGAGGGTTTTCTG-3=) designed in
this study (with initial denaturation at 94°C for 5min, 30 cycles of
denaturation at 94°C for 30 s, annealing at 58°C for 60 s, and
extension at 72°C for 60 s, and a final extension at 72°C for 5min).
This study represents one of the very few reports of the acquisition
of carbapenemase-encoding genes mediated by a class 3 integron
(18, 19), and to our knowledge, those are the first such genes to
have been found in CPE isolates. Notable is the fact that two iso-
lates (Kp17060 and Kp17061, Table 1) were collected on the same
day from patients admitted in the same hospital room, suggesting
that organisms were transferred through direct contact. Also, we
confirmed the location of the blaVIM-2 gene in a class 1 integron, as
previously described (4).
In our study, among the 15 isolates with CPE-encoding
genes randomly selected to be tested for transferability by broth
mating-out assays using recipient rifampin-resistant (Rifr) or
streptomycin-resistant (Strr) E. coli C600 and sodium azide-re-
sistant (NaN3
r) E. coli J53 strains (11), we obtained 10 (66.7%)
transconjugants with blaKPC-3-harboring plasmids. Using PCR-
based replicon typing to type the resistance plasmids (20), we
observed the transfer of an IncF group harboring the blaKPC-3 and
blaTEM-1 genes within the recipient NaN3
r E. coli J53 (n 9) and
RifrE. coliC600 (n 1) strains. The location of the blaKPC gene has
been observed in plasmids of various sizes, belonging to the IncF,
IncL/M, and IncN plasmid types, and also on small rolling circle-
replicating (RCR) plasmids that are not self-transmissible but can
mobilized in trans by coresident conjugative plasmids (2). In this
study, we identified the IncF plasmid in different species, such as
Klebsiella spp. and Enterobacter spp., suggesting that the dissemi-
nation of the blaKPC-3 gene is due to lateral gene transfer rather
than clonal spread. In general, the MICs of the transconjugants
showed similar susceptibility profiles as those of the donor strains
with nonsusceptibility to meropenem, ertapenem, cefotaxime,
ceftazidime, gentamicin, and trimethoprim, as well as those with
susceptibility to colistin and tigecycline. Regarding imipenem
(n  7), doripenem (n  9), and ciprofloxacin (n  9), the ma-
jority of the transconjugants were susceptible in comparison to
the clinical isolates, with MICs from 8 mg/liter to 1 mg/liter for
imipenem, 2 mg/liter to 0.25 mg/liter for doripenem, and 0.125
mg/liter to0.06 mg/liter for ciprofloxacin.
Multilocus sequence typing ofK. pneumoniae (n 26) isolates
(http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html) showed a
high degree of genetic diversity, as they were from distinct se-
quence types (STs), namely, ST14, ST15, ST34, ST59, ST147,
ST416, and ST698, and from the two novel STs ST960 and ST1138
(Table 2).Overall, 10 STswere observed to be associatedwithKPC
production, with ST147 (n 4), ST1138 (n 4), and ST15 (n
TABLE 2 Characteristics of 35 CPE isolates detected in this study and of the 10 transconjugant strains obtaineda
Species (no.) encountered by
carbapenemase typeb MLST (no.) Hospital code/yr of isolation (no.) Other -lactamase(s) detectedc
KPC-3 (Tn4401b)
E. aerogenes (3) A/2012, E/2011, H/2013 TEM-1, (OXA-30), (CTX-M-15)
E. cloacae (2) E/2010, E/2012 ACT-type, (TEM-1), (OXA-30)
E. coli (n 3) ST58 G/2013 TEM-1
K. pneumoniae (22) ST11 (2) E/2012, E/2013 TEM-1, SHV-11, (OXA-30), (CTX-M-15)
ST14 (3) F/2010, G/2012, G/2013 TEM-1, SHV-1
ST15 (4) G/2012 (2), G/2012 (1), G/2013 (1) TEM-1, SHV-1, CTX-M-15
ST34 (1) E/2011 TEM-1, SHV-26
ST59 (1) E/2011 TEM-1
ST147 (4) E/2012 (2), E/2012 (2) TEM-1, SHV-11
ST416 (1) B/2011 TEM-1, SHV-14, OXA-30, CTX-M-15
ST698 (1) G/2012 TEM-1, SHV-11, CTX-M-15
ST960 (1)d I/2011 TEM-1, SHV-164
ST1138 (4)d D/2011 (1), D/2011 (1), E/2011 (2) TEM-1, SHV-36
GES-5 (intI3)
K. pneumoniae (4) ST231 C/2012 (2), C/2013 (2) TEM-1, SHV-12, SHV-1
VIM-2 (intI1)
K. oxytoca (1) H/2010 SHV-12
a Isolates that successfully transferred the KPC-3 to recipient strains are underlined. All clinical isolates and their respective transconjugant isolates contained KPC-3- and TEM-1-
harboring IncF(FII) plasmids.
b Parentheses indicate the mobile genetic element associated with the respective carbapenemase-encoding gene.
c Parentheses indicate the variable presence of an antibiotic resistance determinant.
d MLST first described here.
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4) being the most prevalent types. ST147 is an important clone
associated with this resistancemechanismworldwide, namely due
to VIM-, KPC-, and NDM-producingK. pneumoniae isolates (21,
22), while ST1138 was first described here in 4 KPC-3-producing
K. pneumoniae isolates coexpressing TEM-1 and SHV-36 (Table
2). Interestingly, isolates belonging to the well-known lineage of
K. pneumoniae ST258, which plays a major role in the global
spread of KPC carbapenemases (23), were not found. Regarding
KPC-producing E. coli (n  3) (http://mlst.warwick.ac.uk/mlst
/dbs/Ecoli), all isolates belonged to ST58.
In conclusion, this study provides new data regarding the mo-
lecular epidemiology of CPE in Portugal, with the emergence of
the carbapenemase KPC-3. Indeed, this study suggests that the
dissemination of the blaKPC-3 gene occurs due to the dispersion of
Tn4401d, carried by an IncF plasmid and spread both by poly-
clonal K. pneumoniae and by Enterobacter aerogenes, Enterobacter
cloacae, and E. coli clinical strains.
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